| Literature DB >> 25404942 |
Sachin C Deorukhkar1, Santosh Saini1, Stephen Mathew1.
Abstract
The very nature of infectious diseases has undergone profound changes in the past few decades. Fungi once considered as nonpathogenic or less virulent are now recognized as a primary cause of morbidity and mortality in immunocompromised and severely ill patients. Candida spp. are among the most common fungal pathogens. Candida albicans was the predominant cause of candidiasis. However, a shift toward non-albicans Candida species has been recently observed. These non-albicans Candida species demonstrate reduced susceptibility to commonly used antifungal drugs. In the present study, we investigated the prevalence of non-albicans Candida spp. among Candida isolates from various clinical specimens and analysed their virulence factors and antifungal susceptibility profile. A total of 523 Candida spp. were isolated from various clinical specimens. Non-albicans Candida species were the predominant pathogens isolated. Non-albicans Candida species also demonstrated the production of virulence factors once attributed to Candida albicans. Non-albicans Candida demonstrated high resistance to azole group of antifungal agents. Therefore, it can be concluded that non-albicans Candida species have emerged as an important cause of infections. Their isolation from clinical specimen can no longer be ignored as a nonpathogenic isolate nor can it be dismissed as a contaminant.Entities:
Year: 2014 PMID: 25404942 PMCID: PMC4227454 DOI: 10.1155/2014/615958
Source DB: PubMed Journal: Interdiscip Perspect Infect Dis ISSN: 1687-708X
Figure 1Clinical samplewise distribution of Candida isolates.
Candida spp. isolated from various clinical specimens.
|
| Urine | Vaginal swab | Oropharyngeal swab | Blood | CSF | Miscellaneous | Total |
|---|---|---|---|---|---|---|---|
|
| 71 | 52 | 39 | 06 | 02 | 22 | 192 |
|
| 51 | 31 | 14 | 07 | — | 13 | 116 |
|
| 24 | 41 | 11 | 08 | 04 | 05 | 93 |
|
| 14 | 11 | 08 | — | — | 21 | 54 |
|
| 15 | 03 | 07 | — | — | 05 | 30 |
|
| 04 | — | 09 | — | — | 05 | 18 |
|
| 02 | 02 | 06 | — | — | 01 | 11 |
|
| — | 02 | 07 | — | — | — | 09 |
|
| |||||||
| Total | 181 | 142 | 101 | 21 | 06 | 72 | 523 |
Production of various virulence factors by Candida spp.
|
| ABEC (%) | Biofilm formation (%) | Coagulase production (%) | Haemolysin production (%) | Phospholipase production (%) | Proteinase production (%) |
|---|---|---|---|---|---|---|
|
| 163 (83.1) | 143 (72.9) | 112 (57.1) | 168 (85.7) | 172 (87.7) | 156 (79.5) |
|
| 74 (63.7) | 86 (74.1) | 65 (56.1) | 73 (62.9) | 95 (81.8) | 89 (76.7) |
|
| 56 (60.2) | 59 (63.4) | 45 (48.3) | 62 (66.6) | 61 (65.5) | 56 (60.2) |
|
| 16 (29.6) | 12 (22.2) | 8 (14.8) | 13 (24.1) | 12 (22.2) | 12 (22.2) |
|
| 8 (26.6) | 7 (23.3) | — | 6 (20) | 9 (30) | 7 (23.3) |
|
| 4 (22.2) | 5 (27.7) | 3 (16.6) | 4 (22.2) | 6 (33.3) | 5 (27.7) |
|
| 3 (27.2) | 3 (27.2) | 2 (18.1) | 2 (18.1) | 3 (27.2) | 3 (27.2) |
|
| 5 (55.5) | — | — | 3 (33.3) | 1 (11.1) | 6 (66.6) |
Antifungal susceptibility profile of Candida isolates.
|
| Antifungal agent |
| SDD (%) |
|
|---|---|---|---|---|
|
| Amphotericin B | 164 (85.4) | 8 (4.1) | 20 (10.4) |
| Fluconazole | 121 (63.1) | 6 (3.1) | 65 (33.8) | |
| Itraconazole | 116 (60.4) | 2 (1.1) | 74 (38.5) | |
| Ketoconazole | 112 (45.3) | — | 80 (41.7) | |
|
| ||||
|
| Amphotericin B | 98 (84.4) | 9 (7.7) | 9 (7.7) |
| Fluconazole | 69 (59.5) | 3 (2.6) | 44 (37.9) | |
| Itraconazole | 65 (56.1) | 2 (1.7) | 49 (42.2) | |
| Ketoconazole | 63 (54.3) | 4 (3.5) | 49 (42.2) | |
|
| ||||
|
| Amphotericin B | 85 (91.3) | — | 8 (8.7) |
| Fluconazole | 49 (52.7) | 6 (6.5) | 38 (40.8) | |
| Itraconazole | 50 (53.8) | — | 43 (46.2) | |
| Ketoconazole | 51 (54.8) | 2 (2.1) | 60 (64.5) | |
|
| ||||
|
| Amphotericin B | 51 (94.4) | — | 3 (5.6) |
| Fluconazole | 34 (62.9) | 1 (1.9) | 19 (35.2) | |
| Itraconazole | 31 (57.4) | — | 23 (42.6) | |
| Ketoconazole | 32 (59.2) | 2 (3.7) | 20 (37.1) | |
|
| ||||
|
| Amphotericin B | 28 (93.3) | — | 2 (6.7) |
| Fluconazole | 16 (53.3) | 3 (10) | 11 (36.7) | |
| Itraconazole | 19 (63.3) | 2 (6.7) | 12 (40) | |
| Ketoconazole | 16 (53.3) | 3 (10) | 11 (36.7) | |
|
| ||||
|
| Amphotericin B | 15 (83.4) | 2 (11.1) | 1 (5.5) |
| Fluconazole | 11 (61.1) | 2 (11.1) | 5 (27.8) | |
| Itraconazole | 10 (55.5) | 2 (11.1) | 6 (33.4) | |
| Ketoconazole | 11 (61.1) | 2 (11.1) | 5 (27.8) | |
|
| ||||
|
| Amphotericin B | 11 (100) | — | — |
| Fluconazole | 7 (63.6) | 2 (18.2) | 2 (18.2) | |
| Itraconazole | 6 (54.5) | 2 (18.2) | 3 (27.3) | |
| Ketoconazole | 8 (72.7) | — | 3 (27.3) | |
|
| ||||
|
| Amphotericin B | 9 (93.3) | — | 2 (6.7) |
| Fluconazole | 3 (33.3) | 3 (33.3) | 3 (33.3) | |
| Itraconazole | 4 (44.5) | 2 (22.2) | 3 (33.3) | |
| Ketoconazole | 3 (33.3) | — | 6 (66.7) | |